United States

People: AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

18 Apr 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

von Bohlen und Halbach, Friedrich 

Dr. Friedrich von Bohlen und Halbach, Ph.D., has been Non-Executive Independent Director of AC Immune Ltd since October 2015. He is co-founder and managing director of dievini Hopp BioTech holding GmbH & Co. KG. He brings industry experience from Fresenius AG, FAG Kugelfischer, and WASAG-Chemie AG, founded LION bioscience AG in 1997 (now SYGNIS Pharma AG) and served as the company’s Chief Executive Officer. He is a board member of various companies of the dievini portfolio and Chairman of Apogenix AG, CureVac AG and Novaliq GmbH. He holds a Ph.D. in Neurobiology from the Swiss Federal Institute of Technology in Zurich, Switzerland.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --